Ovid Therapeutics (OVID) Metrics: History & Chart

Ovid Therapeutics Inc.(OVID)

Biotechnology · New York City, NY

$2.38+0.04 (+1.82%)

Delayed quote: Oct 6, 2026, 1:50 PM EDT

About Ovid Therapeutics Inc.

Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins. To bolster its research and development efforts, Ovid maintains licensing and collaborative agreements with prominent entities such as Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Marinus Pharmaceuticals, Inc. Established in 2014, the company's corporate headquarters are situated in New York, New York.

New York City, NY

23 employees

www.ovidrx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Margaret Alexander

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	-4.88%
30D Total Return	-16.43%
YTD Total Return	+43.56%
1Y Total Return	+27.17%
3Y Total Return	-34.45%
5Y Total Return	-30.35%
10Y Total Return	N/A
15Y Total Return	N/A
20Y Total Return	N/A

2026	+43.56%
2025	+74.57%
2024	-71.00%
2023	+73.12%
2022	-42.06%
2021	+38.96%
2020

CAGR TTM	+27.03%
CAGR 3Y	-13.13%
CAGR 5Y	-6.98%
CAGR 10Y	N/A
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	1.59
PE Ratio Avg TTM	2.09
PE Ratio Avg 3Y	2.09
Current VS TTM Avg	-23.85%
Current VS 3Y Avg	-23.85%
Current VS 5Y Avg	-23.85%

All Metrics

OVID Valuation Metrics

OVID Stock Price Metrics

OVID Dividend Metrics

OVID Growth Rate Metrics

OVID Discounted Cash Flow Metrics

OVID Returns By Period

OVID Yearly Returns

OVID Average Annual Returns By Period (CAGR)

OVID Revenue Metrics

OVID PE Ratio Metrics

OVID PS Ratio Metrics

OVID PB Ratio Metrics

OVID Price to Free Cash Flow Ratio Metrics

OVID Debt to Equity Ratio Metrics

OVID PEG Ratio Metrics

OVID FCF Yield

OVID Earnings Yield

OVID EBITDA Yield

OVID OCF Yield

OVID EV/EBIT Ratio Metrics

OVID EV/EBITDA Ratio Metrics

OVID EV/Assets Ratio Metrics

OVID EV/Sales Ratio Metrics

OVID Current Ratio Metrics

OVID Quick Ratio Metrics

OVID ROIC Metrics

OVID Return on Assets Metrics

OVID Return on Equity Metrics

OVID Net Profit Margin Metrics

OVID Gross Profit Margin Metrics

OVID Tax Rate Metrics

PS Ratio	109.00
PS Ratio Avg TTM	21.96
PS Ratio Avg 3Y	64.03
Current VS TTM Avg	+396.35%
Current VS 3Y Avg	+70.23%
Current VS 5Y Avg	+69.68%

PB Ratio	0.82
PB Ratio Avg TTM	1.72
PB Ratio Avg 3Y	1.48
Current VS TTM Avg	-52.23%
Current VS 3Y Avg	-44.65%
Current VS 5Y Avg	-41.71%

PFCF Ratio	1.60
PFCF Ratio Avg TTM	1.91
PFCF Ratio Avg 3Y	1.91
Current VS TTM Avg	-16.39%
Current VS 3Y Avg	-16.39%
Current VS 5Y Avg	-16.39%

Debt/Equity Ratio	0.06
Debt/Equity Ratio Avg TTM	0.15
Debt/Equity Ratio Avg 3Y	0.19
Current VS TTM Avg	-58.58%
Current VS 3Y Avg	-67.78%
Current VS 5Y Avg	-55.22%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	62.50%
FCF Yield Avg TTM	52.11%
FCF Yield Avg 3Y	52.11%
Current VS TTM Avg	+19.95%
Current VS 3Y Avg	+19.95%
Current VS 5Y Avg	+19.95%

Earnings Yield	62.95%
Earnings Yield Avg TTM	49.38%
Earnings Yield Avg 3Y	49.38%
Current VS TTM Avg	+27.48%
Current VS 3Y Avg	+27.48%
Current VS 5Y Avg	+27.48%

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	0.01
Ev/Ebit Ratio Avg TTM	0.19
Ev/Ebit Ratio Avg 3Y	0.19
Current VS TTM Avg	-94.80%
Current VS 3Y Avg	-94.80%
Current VS 5Y Avg	-94.80%

Ev/Ebitda Ratio	0.01
Ev/Ebitda Ratio Avg TTM	0.19
Ev/Ebitda Ratio Avg 3Y	0.19
Current VS TTM Avg	-94.66%
Current VS 3Y Avg	-94.66%
Current VS 5Y Avg	-94.66%

Ev/Assets Ratio	0.75
Ev/Assets Ratio Avg TTM	1.16
Ev/Assets Ratio Avg 3Y	0.95
Current VS TTM Avg	-35.16%
Current VS 3Y Avg	-20.85%
Current VS 5Y Avg	-8.65%

Ev/Sales Ratio	109.87
Ev/Sales Ratio Avg TTM	17.41
Ev/Sales Ratio Avg 3Y	54.57
Current VS TTM Avg	+531.20%
Current VS 3Y Avg	+101.35%
Current VS 5Y Avg	+132.66%

Current Ratio	12.39
Current Ratio Avg TTM	8.49
Current Ratio Avg 3Y	8.06
Current VS TTM Avg	+45.98%
Current VS 3Y Avg	+53.73%
Current VS 5Y Avg	+4.83%

Quick Ratio	12.39
Quick Ratio Avg TTM	8.49
Quick Ratio Avg 3Y	8.06
Current VS TTM Avg	+45.98%
Current VS 3Y Avg	+53.73%
Current VS 5Y Avg	+4.83%

ROIC	(26.29%)
ROIC Avg 3Y	(53.09%)
ROIC Avg 5Y	(49.44%)
Current VS 3Y Avg	+50.48%
Current VS 5Y Avg	+46.82%
Current VS 10Y Avg	+62.04%

ROA	(14.87%)
ROA Avg TTM	(6.54%)
ROA Avg 3Y	(9.39%)
Current VS TTM Avg	-127.45%
Current VS 3Y Avg	-58.36%
Current VS 5Y Avg	-67.08%

ROE	(16.43%)
ROE Avg TTM	(38.33%)
ROE Avg 3Y	(43.49%)
Current VS TTM Avg	+57.14%
Current VS 3Y Avg	+62.22%
Current VS 5Y Avg	+62.19%

Net Profit Margin	(2178.90%)
Net Profit Margin Avg TTM	(1997.42%)
Net Profit Margin Avg 3Y	(6049.88%)
Current VS TTM Avg	-9.09%
Current VS 3Y Avg	+63.98%
Current VS 5Y Avg	+65.10%

Gross Profit Margin	100.00%
Gross Pft Margin Avg TTM	80.00%
Gross Pft Margin Avg 3Y	100.00%
Current VS TTM Avg	+25.00%
Current VS 3Y Avg	0.00%
Current VS 5Y Avg	0.00%

Tax Rate	0.00%
Tax Rate Avg 3Y	0.00%
Tax Rate Avg 5Y	0.09%
Current VS 3Y Avg	N/A
Current VS 5Y Avg	-100.00%
Current VS 10Y Avg	-100.00%